Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity

Citations Over TimeTop 1% of 2014 papers

Abstract

Combining chemotherapeutics is a promising method of improving cancer treatment; however, the clinical success of combination therapy is limited by the distinct pharmacokinetics of combined drugs, which leads to nonuniform distribution. In this study, we report a new robust approach to load two drugs with different hydrophilicities into a single cross-linked multilamellar liposomal vesicle (cMLV) to precisely control the drug ratio that reaches the tumor in vivo. The stability of cMLVs improves the loading efficiency and sustained release of doxorubicin (Dox) and paclitaxel (PTX), maximizing the combined therapeutic effect and minimizing the systemic toxicity. Furthermore, we show that the cMLV formulation maintains specific drug ratios in vivo for over 24 h, enabling the ratio-dependent combination synergy seen in vitro to translate to in vivo antitumor activity and giving us control over another parameter important to combination therapy. This combinatorial delivery system may provide a new strategy for synergistic delivery of multiple chemotherapeutics with a ratiometric control over encapsulated drugs to treat cancer and other diseases.

Related Papers

• → Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations(2015)44 cited
• → Effect of liposome type and membrane fluidity on drug–membrane partitioning analyzed by immobilized liposome chromatography(2001)68 cited
• → Complement Dependent and Independent Liposome Uptake by Peritoneal Macrophages: Cholesterol Content Dependency.(1998)17 cited
• Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer： A case report(2006)
• Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients(2006)